Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: PR Newswire
NORTH CHICAGO, Ill., Oct. 26, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new pooled analyses and post hoc results from the Phase 3 trials of AGN-190584 (pilocarpine HCl ophthalmic solution 1.25%), an investigational novel treatment for presbyopia, at Academy 2021, the annual meeting of the American Academy of Optometry, November 3-6. Presentations will include clinical results for near and intermediate vision, functional near vision, efficacy for post-LASIK patients, and the patient experience."We look forward to sharing data from AGN-190584's Phase 3 study results with attendees at Academy 2021 that not only show an improvement in near vision in presbyopia patients, but also shed light on how practitioners may implement this treatment in the real world, pending approval," said Michael R. Robinson, M.D., vice president, global therapeutic area head, eye care, AbbVie. "Optometrists well understand the daily challenges of those li
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Global Transplant Market Forecast Report 2024-2029: Investment by Major Players like Abbvie and Arthrex in Organ Transplantation is Fueling Market Growth [Yahoo! Finance]Yahoo! Finance
- Glaucoma Global Clinical Trials Review 2024: Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Points Status [Yahoo! Finance]Yahoo! Finance
- Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics [Yahoo! Finance]Yahoo! Finance
- Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands [Yahoo! Finance]Yahoo! Finance
- Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest BrandsPR Newswire
ABBV
Earnings
- 2/2/24 - Beat
ABBV
Sec Filings
- 4/3/24 - Form 8-K
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- ABBV's page on the SEC website